Evaluation of Swaziland's hub-and-spoke model for decentralizing access to antiretroviral therapy services

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 1, 2015, Pages e1-e12

  Auld, Andrew F ^a   Kamiru, Harrison ^b   Azih, Charles ^c   Baughman, Andrew L ^a   Nuwagaba Biribonwoha, Harriet ^b   Ehrenkranz, Peter ^d   Agolory, Simon ^a   Sahabo, Ruben ^b   Ellerbrock, Tedd V ^a   Okello, Velephi ^c   Bicego, George ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Columbia University ^*  (United States)

^c Ministry of Health   (Swaziland)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antiretroviral therapy; decentralization; down referral; outcomes; Swaziland

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DECENTRALIZATION; DOWN REFERRAL; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWAZILAND; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MEDICATION COMPLIANCE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PREGNANCY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DELIVERY OF HEALTH CARE; FEMALE; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; SWAZILAND;

EID: 84928411024     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000547     Document Type: Article

References (55)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. Tanser F, Bärnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966-971.
3. Kredo T, Ford N, Adeniyi FB, et al. Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev. 2013; 6:CD009987.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed February 17, 2014.
5. Bicego GT, Nkambule R, Peterson I, et al. Recent patterns in populationbased HIV prevalence in Swaziland. PLoS One. 2013;8:e77101.
6. Brennan AT, Long L, Maskew M, et al. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011;25:2027-2036.
7. Long L, Brennan A, Fox MP, et al. Treatment outcomes and costeffectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011;8:e1001055.
8. Chan AK, Mateyu G, Jahn A, et al. Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model. Trop Med Int Health. 2010;15 (suppl 1):90-97.
9. Massaquoi M, Zachariah R, Manzi M, et al. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg. 2009;103:594-600.
10. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach-2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed June 6, 2014.
11. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach- 2010 revision. Available at: http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf. Accessed June 6, 2014.
12. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-457.
13. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7:147-177.
14. Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol. 2009;60:549-576.
15. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: J. Wiley & Sons; 1987.
16. Royston P. Multiple imputation of missing values. Stata J. 2004;4:227-241.
17. Royston P. Multiple imputation of missing values: update. Stata J. 2005; 5:188-201.
18. Royston P. Multiple imputation of missing values: update of ice. Stata J. 2005;5:527-536.
19. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453.
20. White IR, Royston P. Imputing missing covariate values for the cox model. Stat Med. 2009;28:1982-1998.
21. Royston P, Carlin JB, White IR. Multiple imputation of missing values: new features for mim. Stata J. 2009;9:252-264.
22. Wandeler G, Keiser O, Pfeiffer K, et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr. 2012;59:e9-16.
23. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389-2430.
24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
25. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIVinfected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7:234-244.
26. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS One. 2010;5:e12888.
27. Assefa Y, Kiflie A, Tekle B, et al. Effectiveness and acceptability of delivery of antiretroviral treatment in health centres by health officers and nurses in Ethiopia. J Health Serv Res Policy. 2012;17:24-29.
28. McGuire M, Pinoges L, Kanapathipillai R, et al. Treatment initiation, program attrition and patient treatment outcomes associated with scale-up and decentralization of HIV care in rural Malawi. PLoS One. 2012;7: e38044.
29. Humphreys CP, Wright J, Walley J, et al. Nurse led, primary care based antiretroviral treatment versus hospital care: a controlled prospective study in Swaziland. BMC Health Serv Res. 2010;10:229.
30. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405-411.
31. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364: 2199-2207.
32. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010;24:2263-2270.
33. African Development Bank. Migration patterns, trends and policy issues in Africa. Available at: http://www.afdb.org/fileadmin/uploads/afdb/Documents/Project-related-Procurement/WORKING%20119%20word% 20document%20AA.pdf. Accessed June 6, 2014.
34. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290-1294.
35. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the multicenter AIDS Cohort Study. AIDS. 2001;15:735-746.
36. Centers for Disease Control and Prevention. Differences between HIVinfected men and women in antiretroviral therapy outcomes-six African countries, 2004-2012. MMWR Morb Mortal Wkly Rep. 2013;62:946-952.
37. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health. 2009;14:722-731.
38. Owens IPF. Sex differences in mortality rate. Science. 2002;297:2008.
39. Suthar AB, Ford N, Bachanas PJ, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10:e1001496.
40. Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, et al. Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One. 2012;7:e37125.
41. Parrott FR, Mwafulirwa C, Ngwira B, et al. Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS One. 2011;6:e27917.
42. Tiyou A, Belachew T, Alemseged F, et al. Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resourcelimited setting of southwest ethiopia. AIDS Res Ther. 2010;7:39.
43. Amberbir A, Woldemichael K, Getachew S, et al. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.
44. Cunningham WE, Hays RD, Duan N, et al. The effect of socioeconomic status on the survival of people receiving care for HIV infection in the United States. J Health Care Poor Underserved. 2005;16:655-676.
45. McFarland W, Chen S, Hsu L, et al. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic Syndr. 2003;33:96-103.
46. African Books Collective. Lobola: It's Implications for Women's Reproductive Rights. Available at: http://www.africanbookscollective.com/books/lobola-its-implications-for-womens-reproductive-rights. Accessed June 6, 2014.
47. Leroy V, Malateste K, Rabie H, et al. Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr. 2013;62:208-219.
48. Forster M, Bailey C, Brinkhof MW, et al. Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ. 2008;86:939-947.
49. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011; 56:e1-8.
50. Musheke M, Bond V, Merten S. Deterrents to HIV-patient initiation of antiretroviral therapy in urban Lusaka, Zambia: a qualitative study. AIDS Patient Care STDS. 2013;27:231-241.
51. Musheke M, Bond V, Merten S. Individual and contextual factors influencing patient attrition from antiretroviral therapy care in an urban community of Lusaka, Zambia. J Int AIDS Soc. 2012;15(suppl 1):1-9.
52. Duff P, Kipp W, Wild TC, et al. Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc. 2010;13:37.
53. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375:1278-1286.
54. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One. 2008;3: e1725.
55. Geng EH, Glidden DV, Bangsberg DR, et al. A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol. 2012;175:1080-1087.